This site is intended for health professionals only

Wednesday 24 April 2019
Share |

Topic: Allergy

April 15, 2019
Identification of the allergic triggers of rhinitis is crucial in order to implement adequate avoidance measures in both atopic and non-atopic patients; moreover, this identification can help administer specific therapies, such as allergen immunotherapy
Rhinitis is an inflammatory disorder of the nasal mucosa clinically defined by two or more symptoms of nasal itching, sneezing, anterior or posterior rhinorrhoea, and nasal blockage.1
 
April 12, 2019
Scientists could be a step closer to providing more precise pollen forecasts to the 25% of the UK population who live with either asthma or hay fever
A study published in Nature Ecology & Evolution has shown that it is not just the overall 'load' of grass pollen in the air that could cause those particularly bad days for asthma and hay fever sufferers.1 Days that see increased asthma attacks or intense hay fever could be related to the release of pollen from particular grass species.
 
April 12, 2019
An eight-year hunt for the cells that drive the extreme childhood food allergy eosinophilic oesophagitis has identified a potential new way to treat the disease while also raising questions about a dietary supplement taken to reduce bowel inflammation
An eight-year hunt for the cells that drive the extreme childhood food allergy eosinophilic esophagitis (EoE) has identified a potential new way to treat the disease while also raising questions about a dietary supplement often taken to reduce bowel inflammation.
 
The study, led by experts at Cincinnati Children's Hospital Medical Center, is posted online in the Journal of Clinical Investigation1 and will be published in print in May. 
 
April 12, 2019
Researchers have effectively prevented the binding of peanut allergens with IgE to suppress the allergic reaction to peanuts using a first-in-class design of allergen-specific inhibitors
In a study published in the Proceedings of the National Academy of Sciences, researchers at the University of Notre Dame in the US have effectively prevented the binding of peanut allergens with IgE to suppress the allergic reaction to peanuts using a first-in-class design of allergen-specific inhibitors.
 
April 5, 2019
An international research team has found that patients with the lung disease bronchiectasis also often display sensitivity to airborne allergens, and has highlighted the particular role that fungi appear to play
An international research team from Singapore has found that patients with the lung disease bronchiectasis also often display sensitivity to airborne allergens, and has highlighted the particular role that fungi appear to play.
 
Their discovery suggests that bronchiectasis patients should be examined for a range of allergies, since the treatment for allergies already exists and controlling them could prevent the bronchiectasis from worsening.
 
March 28, 2019
ARTEMIS data demonstrate that most patients exceeded what are considered to be protective levels well before a full year of treatment
Aimmune has announced that its Phase III European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (AR101 Trial in Europe Measuring oral Immunotherapy Success), met its primary efficacy endpoint. 
 
March 26, 2019
Results presented at ENDO 2019, the Endocrine Society's annual meeting
Researchers using the world's largest twin registry to study seven autoimmune diseases found the risk of developing the seven diseases is largely inherited, but that some diseases are more closely related than others.
 
March 19, 2019
Diagnostic procedures in allergy have been greatly modified (and improved) by molecular allergy tools that not only identify the molecular allergen that causes sensitisation but also provide personalised therapeutic solutions

Allergies are the most common immune system disorders. Their prevalence is continuously increasing, especially in Western countries, where they affect more than 25% of the population.1

March 18, 2019
The role of the allergy specialist is critical in risk identification, diagnosis and management of potentially severe allergic reactions in both children and adults
Allergies are a major ongoing problem, especially in Western countries. Currently, it is estimated that about a quarter of the world's population suffers from some type of allergy, mainly due to allergic rhinitis or allergic bronchial asthma.
 
However, the most dangerous reactions (anaphylaxis) usually occur through allergic reactions to foods, drugs and Hymenoptera (for example, wasps, bees, ants, etc) bites.
 
The Big Eight
March 4, 2019
CHMP recommends Dupixent® (dupilumab) for use in adults and adolescents 12 years and older as add on maintenance treatment for certain forms of severe asthma
The European Medicines Agency’s
Committee for
February 28, 2019
After completing up to four years of egg oral immunotherapy treatment, certain study participants were able to safely incorporate egg into their diet for five years
New research regarding egg oral immunotherapy (eOIT) has been presented at the annual American Academy of Allergy, Asthma and Immunology conference in San Francisco.
 
February 20, 2019
Researchers at the University of Helsinki have found that pollen allergen immunotherapy has favourable effects on the molecular events and microbiome profile in the nasal membrane
Birch pollen allergic rhinitis is the most common chronic disorder in the Northern part of the globe, and it attributes to significant morbidity and economic burden.
 
According to a study by researchers at the University of Helsinki, pollen allergen immunotherapy has favourable effects on the molecular events and microbiome profile in the nasal membrane.
 
January 23, 2019
Those aged 18-29 are the most likely to suffer an asthma attack and least likely to receive life-saving asthma care than any other age group, research has revealed.

Those aged 18-29 are the most likely to suffer an asthma attack and least likely to receive life-saving asthma care than any other age group, research has revealed.
 
Two-thirds (67%) of patients in this group are not receiving basic asthma care – higher than any other age group – a survey of more than 10,000 asthma patients by the charity Asthma UK revealed.
 
Patients in this age group are also twice as likely to receive emergency asthma care than patients aged over 60, the charity said.
 

January 15, 2019
The findings of a study published in Nature Medicine might inform research to develop microbiome-based therapies to prevent or treat food allergy
Scientists at the University of Chicago have found that gut microbes from healthy human infant donors transplanted into mice protected animals exposed to milk from experiencing allergic reactions, while gut microbes transplanted from infants allergic to milk did not.
 
The study, published in Nature Medicine,1 was supported in part by NIH’s National Institute of Allergy and Infectious Diseases. 
 
December 17, 2018
Omalizumab prefilled syringe is the first and only biologic to receive European Commission approval for self-administration in severe allergic asthma and chronic spontaneous urticaria
Novartis has announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment.
 
With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU.
 
December 17, 2018
There are scant data that describe how often pregnant women deliberately stop eating a specific food item in order to prevent future food allergies in their newborns
Pregnant women routinely swear off alcohol and tobacco to boost their chances of having a healthy baby. What about common food allergens like nuts and milk?
 
December 17, 2018
The researchers hope the Pediatric Asthma Risk Score will become the most common tool used by medical practitioners to predict asthma and help prevent the common airway disease from developing
Scientists at Cincinnati Children's Hospital Medical Center in the US have created and tested a decision tool that appears to be the most accurate, non-invasive method yet developed to predict asthma in young children.
 
The researchers hope the Pediatric Asthma Risk Score (PARS) will become the most common tool used by medical practitioners to predict asthma and help prevent the common airway disease from developing.
 
December 6, 2018
Nexvax2 is currently the only disease-modifying therapeutic in clinical development for patients with coeliac disease
December 4, 2018
The researchers used a next-generation peptide-based immunoassay to subdivide allergenic milk proteins into smaller peptide fragments — called epitopes — and measured the reactivity of the epitopes to a patient’s IgE/IgG4 antibodies
AllerGenis has reported research results in The Journal of Allergy and Clinical Immunology(JACI) that demonstrate the ability to predict, with significant accuracy, milk allergy patients’ outcomes before milk oral immunotherapy treatment (Milk-OIT) is administered, using the company’s novel milk allergy diagnostic assay.  
 
December 3, 2018
The study explored how different exposures during pregnancy, birth or childhood modulate asthma-related immune responses in children
The prevalence of allergic diseases has increased significantly over the last decades, creating substantial financial and societal burdens. Due to this, researchers are trying to discover new approaches to the prevention and treatment of these diseases. 
 
A new PhD thesis from the University of Eastern Finland shows that there is a link between immune responses and diverse early life exposures, such as obstetric factors, farm dust and air pollution. Some changes in immune responses are visible up until adolescence.
December 1, 2018
An international research team has discovered that the parvalbumin protein that usually triggers allergy is much less allergenic in cartilaginous fish than in bony fish
Fish allergy is one of the most dangerous food allergies, as it is often associated with potentially life-threatening symptoms such as anaphylactic shock.
 
November 22, 2018
AR101 slowly builds up tolerance to peanut allergy, study finds

A new oral biologic drug could reduce the risk of allergic reaction in children and adolescents following accidental peanut exposures, research has shown.
 
AR101 slowly builds up tolerance to peanut allergy, a study published in The New England Journal of Medicine found.
 

November 20, 2018
PALISADE (Peanut Allergy oral Immunotherapy Study of AR101 for Desensitization) was an international, randomised (3:1), double-blind, placebo-controlled, Phase III trial to evaluate the efficacy and safety of AR101 in patients with peanut allergy

Aimmune Therapeutics has announced that the New England Journal of Medicinehas published the full results of the landmark Phase III PALISADE clinical trial of AR101, Aimmune’s investigational biologic oral immunotherapy for desensitisation of patients with peanut allergy. PALISADE is the largest and first successful Phase III peanut allergy immunotherapy trial to date.

October 18, 2018
The researchers found clues as to why the allergy immunisation takes so long and how the chances of success can be determined at a very early stage
Allergen-specific immunotherapy can make everyday life much more pleasant for allergy sufferers and provide long-term protection against asthma. It is unclear, however, what exactly happens during this treatment.